NORTH CHICAGO (dpa-AFX) - Zealand Pharma AS signed a licensing agreement with Abbott Laboratories (ABT) for the clinical development and commercialization of its compound AP214, intended for the treatment of acute Kindny injuries. The new agreement will cancel the previous licensing agreement with Action Pharma and Zealand would receive $11 million.
Copyright RTT News/dpa-AFX
© 2012 AFX News
